(Total Views: 541)
Posted On: 04/09/2025 1:32:50 PM
Post# of 154899
Thanks Ohm
Excerpt: "Progression-free survival as determined by central review was consistent with investigator assessments (5.5 months with sacituzumab govitecan and 1.7 months with chemotherapy ; hazard ratio for disease progression or death, 0.35; 95% CI, 0.28 to 0.44) (Fig. S3). The median overall survival was 12.1 months (95% CI, 10.7 to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with chemotherapy (hazard ratio for death, 0.48; 95%"
https://www.nejm.org/doi/full/10.1056/NEJMoa2028485
These would be the trial benchmarks LL would be challenging in its own trial??
A four month+- gain for LL would stand against the standard's achievement in gaining its FDA approval? All in addition to zero adverse effects.
Excerpt: "Progression-free survival as determined by central review was consistent with investigator assessments (5.5 months with sacituzumab govitecan and 1.7 months with chemotherapy ; hazard ratio for disease progression or death, 0.35; 95% CI, 0.28 to 0.44) (Fig. S3). The median overall survival was 12.1 months (95% CI, 10.7 to 14.0) with sacituzumab govitecan and 6.7 months (95% CI, 5.8 to 7.7) with chemotherapy (hazard ratio for death, 0.48; 95%"
https://www.nejm.org/doi/full/10.1056/NEJMoa2028485
These would be the trial benchmarks LL would be challenging in its own trial??
A four month+- gain for LL would stand against the standard's achievement in gaining its FDA approval? All in addition to zero adverse effects.
(6)
(0)
